The FASEB Journal, Vol 5, 2437-2455, Copyright © 1991 by The Federation of American Societies for Experimental Biology

REVIEWS

Neutralization of HIV-1: a paradox of humoral proportions

PL Nara, RR Garrity and J Goudsmit
Laboratory of Tumor Cell Biology, National Cancer Institutes-Frederick Cancer Research and Development Center, Maryland 21702-1201.

The production of immunoglobulin capable of neutralizing the infectivity of a virus represents one of the most remarkable molecular accomplishments of the host's available immune defenses. It should be no surprise that a virus that has existed in the parenchyma of the immune system has evolved as an equally dynamic molecule (i.e., viral envelope) for survival. Neutralizing immunoglobulin (Ig) can best serve the host under conditions where the invading pathogen requires a well- defined cell-free state for establishing an infection or transmission. Evidence for a controlling and therefore protective role of neutralizing Ig against lentiviruses has been defined in natural and experimental infections with equine infectious anemia virus of ungulate members in the family equidae. Rapid replication of the virus immediately after infection and its release in a cell-free state leads to the production of neutralizing Ig and subsequent control of the primary viremia. A similar cause-effect relationship exists in humans between the high-titered viremia, observed shortly after HIV-1 infection, and the subsequent production of neutralizing Ig. Partially controlling this acute stage of viral replication by neutralizing Ig and thus preventing an otherwise acute form of immunosuppression or immune complex disease may be viewed paradoxically as a survival property of the virus. Immunologically mediated control, in a Darwinian sense, selects for viruses that have optimized the parameters of longevity and transmission from host to host. This paradox of neutralization in HIV-1 infection appears to be mediated by the convergence of structural and functional roles of the third variable domain (V3) of the external envelope glycoprotein. During infection or envelope-based vaccination, antibody to this cross-reactive, immuno- dominant epitope dominates the antigenic repertoire. Once this occurs, the host is less able to respond to emerging viruses containing closely related V3 structures. Thus a relatively restricted clonal-dominance of the neutralization response results. The V3 domain, apparently in concert with the rest of the molecule, provides an epitope that can tolerate and utilize its conformational flexibility to allow immune escape while maintaining its functional role in infectivity. Sixteen other putative epitopes have been described as being involved in the induction of neutralizing Ig. Currently the biologically functional role of neutralizing Ig to these other epitopes are complicated by a prior lack of knowledge and appreciation of the in vitro variables affecting their measurements.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				J. D. Steckbeck, I. Orlov, A. Chow, H. Grieser, K. Miller, J. Bruno, J. E. Robinson, R. C. Montelaro, and K. S. Cole Kinetic Rates of Antibody Binding Correlate with Neutralization Sensitivity of Variant Simian Immunodeficiency Virus Strains J. Virol., October 1, 2005; 79(19): 12311 - 12320. [Abstract] [Full Text] [PDF]

				J. D. Trujillo, N. M. Kumpula-McWhirter, K. J. Hotzel, M. Gonzalez, and W. P. Cheevers Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses J. Virol., September 1, 2004; 78(17): 9190 - 9202. [Abstract] [Full Text] [PDF]

				R. Pantophlet, I. A. Wilson, and D. R. Burton Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design J. Virol., May 15, 2003; 77(10): 5889 - 5901. [Abstract] [Full Text] [PDF]

				A. de Paulis, G. Florio, N. Prevete, M. Triggiani, I. Fiorentino, A. Genovese, and G. Marone HIV-1 Envelope gp41 Peptides Promote Migration of Human Fc{epsilon}RI+ Cells and Inhibit IL-13 Synthesis Through Interaction with Formyl Peptide Receptors J. Immunol., October 15, 2002; 169(8): 4559 - 4567. [Abstract] [Full Text] [PDF]

				M. I. Quinones-Kochs, L. Buonocore, and J. K. Rose Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response J. Virol., March 27, 2002; 76(9): 4199 - 4211. [Abstract] [Full Text] [PDF]

				S. B. Su, W.-h. Gong, J.-L. Gao, W.-P. Shen, M. C. Grimm, X. Deng, P. M. Murphy, J. J. Oppenheim, and J. M. Wang T20/DP178, an Ectodomain Peptide of Human Immunodeficiency Virus Type 1 gp41, Is an Activator of Human Phagocyte N-Formyl Peptide Receptor Blood, June 1, 1999; 93(11): 3885 - 3892. [Abstract] [Full Text] [PDF]

				S. B. Su, J.-l. Gao, W.-h. Gong, N. M. Dunlop, P. M. Murphy, J. J. Oppenheim, and J. M. Wang T21/DP107, A Synthetic Leucine Zipper-Like Domain of the HIV-1 Envelope gp41, Attracts and Activates Human Phagocytes by Using G-Protein-Coupled Formyl Peptide Receptors J. Immunol., May 15, 1999; 162(10): 5924 - 5930. [Abstract] [Full Text] [PDF]

				J. M. Wang, H. Ueda, O. M. Z. Howard, M. C. Grimm, O. Chertov, X. Gong, W. Gong, J. H. Resau, C. C. Broder, G. Evans, et al. HIV-1 Envelope gp120 Inhibits the Monocyte Response to Chemokines Through CD4 Signal-Dependent Chemokine Receptor Down-Regulation J. Immunol., October 15, 1998; 161(8): 4309 - 4317. [Abstract] [Full Text] [PDF]

				P. W. H. I. Parren, I. Mondor, D. Naniche, H. J. Ditzel, P. J. Klasse, D. R. Burton, and Q. J. Sattentau Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity J. Virol., May 1, 1998; 72(5): 3512 - 3519. [Abstract] [Full Text] [PDF]

				Y. Okamoto, Y. Eda, A. Ogura, S. Shibata, T. Amagai, Y. Katsura, T. Asano, K. Kimachi, K. Makizumi, and M. Honda In SCID-hu Mice, Passive Transfer of a Humanized Antibody Prevents Infection and Atrophic Change of Medulla in Human Thymic Implant due to Intravenous Inoculation of Primary HIV-1 Isolate J. Immunol., January 1, 1998; 160(1): 69 - 76. [Abstract] [Full Text] [PDF]

				K. Tan, J.-h. Liu, J.-h. Wang, S. Shen, and M. Lu Atomic structure of a thermostable subdomain of HIV-1 gp41 PNAS, November 11, 1997; 94(23): 12303 - 12308. [Abstract] [Full Text] [PDF]

				M Piatak Jr, M. Saag, L. Yang, S. Clark, J. Kappes, K. Luk, B. Hahn, G. Shaw, and J. Lifson High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR Science, March 19, 1993; 259(5102): 1749 - 1754. [Abstract] [PDF]

				M. Garcia-Blanco and B. Cullen Molecular basis of latency in pathogenic human viruses Science, November 8, 1991; 254(5033): 815 - 820. [Abstract] [PDF]